FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia

INTRODUCTION: FLT3-ITD mutations occur in approximately 25% of patients with acute myeloid leukemia (AML) and are associated with poor prognosis. Despite initial efficacy, short duration of response and high relapse rates limit clinical use of selective FLT3 inhibitors. Combination approaches with o...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Douglas D., Zhu, Hengrui, Tang, Qiuqiong, Wang, Guangfeng, Min, Ping, Wang, Qixin, Li, Na, Yang, Dajun, Zhai, Yifan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556530/
https://www.ncbi.nlm.nih.gov/pubmed/34710737
http://dx.doi.org/10.1016/j.tranon.2021.101244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556530/
https://www.ncbi.nlm.nih.gov/pubmed/34710737
http://dx.doi.org/10.1016/j.tranon.2021.101244

Ejemplares similares